secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001193125-25-204389
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track designation for Corbus' CRB-701 in recurrent/metastatic HNSCC
--------------------------------------------------------------------------------

- FDA granted Fast Track for CRB-701 to treat HNSCC after prior platinum and anti-PD(L)-1 therapy.
- Second Fast Track designation for CRB-701; first was for cervical cancer in December 2024.
- Phase 1/2 dose optimization data to be presented at ESMO 2025 on October 19, 2025.
- CRB-701 is a next-generation Nectin-4 targeting ADC with site-specific cleavable linker and MMAE payload (DAR 2).
- Ongoing Phase 1/2 trial evaluating safety, PK, and efficacy in advanced solid tumors with high Nectin-4 expression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525204389/0001193125-25-204389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525204389/crbp-20250916.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-204389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer